Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 8/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | DRD3 | P35462 | 2/20 | 0.37 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 3/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13100542 | 0.97 | AGER (0.40) | AGERDRD2DRD3PDE2A | |
| SCHEMBL1283395 | 0.97 | AGER (0.40) | AGERDRD2DRD3PDE2A | |
| SCHEMBL1283364 | 0.94 | AGER (0.40) | AGERDRD2DRD3PDE2A | |
| SCHEMBL1283682 | 0.91 | AGER (0.37) | AGERDRD2DRD3 | |
| SCHEMBL1283608 | 0.91 | AGER (0.37) | AGERDRD2DRD3 | |
| SCHEMBL1283823 | 0.91 | AGER (0.37) | AGERDRD2DRD3 | |
| SCHEMBL1283637 | 0.91 | AGER (0.37) | AGERDRD2DRD3 | |
| SCHEMBL1283502 | 0.91 | AGER (0.37) | AGERDRD2DRD3 | |
| SCHEMBL1283161 | 0.91 | AGER (0.37) | AGERDRD2DRD3 | |
| SCHEMBL1283216 | 0.91 | AGER (0.38) | AGERDRD2DRD3PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA, INC. (US) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | AGER, S100A4, S100B | AGER 1/4885DRD2 4691/4885DRD3 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.